최신 재무제표(Form-10K)에 따르면, Aclarion Inc의 총 자산은 $0이며, 순손실입니다.
ACON의 주요 재무 비율은 무엇인가요?
Aclarion Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Aclarion Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Aclarion Inc 주요 수익원은 Delivery of Nociscan Reports이며, 최신 수익 발표에서 수익은 75,730입니다. 지역별로는 Non-United States이 Aclarion Inc의 주요 시장이며, 수익은 56,040입니다.
Aclarion Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Aclarion Inc의 순손실은 $0입니다.
Aclarion Inc에 부채가 있나요?
no, Aclarion Inc의 부채는 0입니다.
Aclarion Inc의 발행 주식은 몇 주인가요?
Aclarion Inc의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$2.77
시가
$2.83
일일 범위
$2.56 - $2.83
52주 범위
$1.95 - $12.03
거래량
80.6K
평균 거래량
86.6K
배당수익률
--
EPS(TTM)
-9.56
시가총액
$6.3M
ACON란 무엇인가요?
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 11 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.